Association between immunohistochemical expression of topoisomerase II alpha, HER2 and hormone receptors and response to primary chemotherapy in breast cancer

dc.creatorManna, ED
dc.creatorTeixeira, LC
dc.creatorAlvarenga, M
dc.date2006
dc.dateMAY-JUN
dc.date2014-11-17T00:19:12Z
dc.date2015-11-26T17:43:47Z
dc.date2014-11-17T00:19:12Z
dc.date2015-11-26T17:43:47Z
dc.date.accessioned2018-03-29T00:25:53Z
dc.date.available2018-03-29T00:25:53Z
dc.identifierTumori. Pensiero Scientifico Editor, v. 92, n. 3, n. 222, n. 229, 2006.
dc.identifier0300-8916
dc.identifierWOS:000239185900007
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/55047
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/55047
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/55047
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1287687
dc.descriptionThe aim of this study was to evaluate the association between immunohistochemical expression of topoisomerase II alpha, HER2 and hormone receptors and response to primary anthracycline-based chemotherapy in locally advanced breast cancer. We analyzed 109 medical charts of patients treated with primary anthracycline-based chemotherapy in the Women's Integral Health Care Center from 1996 to 2004. The clinical and pathological response to primary chemotherapy was associated with topoisomerase IIa and HER2 expression and hormone receptor, negativity. Statistical analysis was performed using chi-squared, Fisher's exact test and Mann-Whitney test. No statistical association between clinical response and expression of topoisomerase II alpha, HER2 and hormone receptor negativity was found. However, there was an association between complete pathological response and hormone receptor negativity (P = 0.0289). The present study suggested that these markers should not be considered predictors of response to primary anthracycline-based chemotherapy, and prospective studies must be designed for this purpose.
dc.description92
dc.description3
dc.description222
dc.description229
dc.languageen
dc.publisherPensiero Scientifico Editor
dc.publisherRome
dc.publisherItália
dc.relationTumori
dc.relationTumori
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectbreast cancer
dc.subjectHER2
dc.subjectprimary chemotherapy
dc.subjecttopoisomerase II alpha
dc.subjectAnthracycline-based Chemotherapy
dc.subjectComplete Pathological Response
dc.subjectPreoperative Systemic Treatment
dc.subjectSurgical Adjuvant Breast
dc.subjectNeoadjuvant Chemotherapy
dc.subjectGene Amplification
dc.subjectPredictive Markers
dc.subjectPrognostic-significance
dc.subjectInduction Chemotherapy
dc.subjectCell-proliferation
dc.titleAssociation between immunohistochemical expression of topoisomerase II alpha, HER2 and hormone receptors and response to primary chemotherapy in breast cancer
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución